Sandeep Chavan

India's rapid development over the last few decades has brought impressive economic growth, technological advancement, and improved living standards for millions. Yet, the relentless pursuit of quick results, or "quick wins," has also led to unintended consequences that challenge the country's long-term sustainability and stability. In Fast Tracks & Future Risks: The Impact of Quick Wins on India's Future, Sandeep Chavan delves into the complexities of this high-speed progress, examining both its promises and its pitfalls.This book explores how short-term goals, while essential for immediate impact, often come at the cost of comprehensive planning and sustainable development. From urbanization and industrialization to education and employment policies, Chavan uncovers how the focus on rapid results can lead to environmental degradation, regional inequality, and social displacement. He highlights the impact of these policies on India's youth, whose aspirations, opportunities, and migration patterns are intricately shaped by the decisions of today.Balancing critical analysis with actionable insights, Fast Tracks & Future Risks offers a roadmap for building a resilient and inclusive future. It emphasizes the importance of shifting from a purely short-term mindset to a vision that prioritizes long-term growth, environmental stewardship, and social equity. The book calls for policies that nurture innovation, empower local industries, and create sustainable opportunities for India's youth.In this timely and thought-provoking work, Chavan encourages readers to rethink the true meaning of progress and consider the broader implications of the choices we make today. With its compelling arguments and visionary approach, this book serves as both a critique of the present and a guide for crafting a sustainable and prosperous India for generations to come.

Glipizide, an oral hypoglycemic agent, is one of the most commonly prescribed drugs for the treatment of patients with type II diabetes mellitus. It is practically water-insoluble, thus it belongs to class-II of Biopharmaceutical Classification System (BCS). Glipizide has a relatively short elimination half-life (2-4 h), thereby requiring twice daily dosing in large number of patients, which often leads to non-compliance. Thus, there is a strong clinical need and market potential for a dosage form that will deliver glipizide in a controlled manner to a patient needing this therapy, thereby resulting in a better patient compliance. The aim of present investigation was to enhance the solubility by using β-cyclodextrin binary complexation and impart a controlled release in a single formulation in order to reduce dosing frequency.